Shares in AstraZeneca bounced this week after the US government signalled that it is considering fast-track approval for the group’s Covid-19 vaccine. In April AstraZeneca agreed a deal with Oxford University, which originally discovered the vaccine, to develop and distribute it.
The government could ask the US Food and Drug Administration (FDA) to grant an “emergency use authorisation” (EUA) based on data from the final-stage UK trial, rather than wait for the more extended study normally required by US regulators. Such a move, possible as early as September, would allow President Donald Trump to claim he has “turned the tide” on the virus. Not so fast, say Rhys Blakely and Henry Zeffman in The Times. AstraZeneca says it is “too early” to begin talks with US regulators about an EUA. Nonetheless, 17,000 people have been enrolled in trials in Britain, South Africa and Brazil. So if enough data emerged to convince AstraZeneca to apply for an EUA, the FDA would be under pressure to grant it quickly. It has already approved 21 Covid-19 drugs, including an antibody treatment, on an emergency basis.
Meanwhile, says Bloomberg, Pfizer and BioNTech claim that their joint Covid-19 vaccine is “on track” to be submitted for regulatory review “as early as October”. The companies, which recently clinched a $2bn deal to supply 100 million doses to the US government, released more detailed data from early-stage trials suggesting that the drug was “well tolerated” with “mild to moderate fever in fewer than 20% of participants”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Side hustle tax changes: HMRC reforms could save thousands from filing self-assessment tax returnsThe government plans to raise the tax-free threshold for trading income – here is how it could help your side hustle
-
Return to the office: is working from home coming to an end?More and more employers want their staff to return to the office. Is it a good idea?
-
Why CEOs deserve a pay riseOpinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
-
Rolls-Royce stock jumps 15% – could it climb further?Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
-
The power of private marketsInterview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success
-
Global investors have overlooked these top tips in emerging marketsOpinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
-
King Coal has not been dethroned yet — should you buy?The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
-
It’s time to start buying Europe again, says Merryn Somerset WebbOpinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fadesFood-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
